Introduction
Throughout the history of the world, the ones who had confronted the bitterest face of poverty and war had always been the women. As known poverty and war affects human health either directly or indirectly, the effects of this condition on health and status of women in the society should not be ignored. This study intends to cast light on the effects of war and poverty on the reproductive health of women. For this purpose, the face of war affecting the women, the problem of immigration, inequalities in distribution of income based on gender and the effects of all these on the reproductive health of women will be addressed.
War and Women's Health
Famine, synonymous with war and poverty, is clearer for women; war means deep disadvantages such as full destruction, loss of future and uncertainty for women. Wars are conflicts that destroy families, societies and cultures that negatively affect the health of community and cause violation of human rights. According to the data of World Health Organization (WHO) and World Bank, in 2002 wars had been among the first ten reasons which killed the most and caused disabilities. Civil losses are at the rate of 90% within all losses (1) . War has many negative effects on human health. One of these is its effect of shortening the average human life. According to the data of WHO, the average human life is 68.1 years for males and 72.7 years for females. It is being thought that severe military conflicts in Africa shorten the expected lifetime for more than 2 years. In general, WHO had calculated that 269 thousand people had died in 1999 due to the effect of wars and that loss of 8.44 million healthy years of life had occurred (2, 3) . Wars negatively affect the provision of health services. Health institutions such as hospitals, laboratories and health centers are direct targets of war. Moreover, the wars cause the migration of qualified health employees, and thus the health services hitches. Assessments made indicate that the effect of destruction in the infrastructure of health continues for 5-10 years even after the finalization of conflicts (3) . Due to resource requirements in the restructuring investments after war, the share allocated to health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and children. While deaths depending on direct violence affect the male population, the indirect deaths kill children, women and elders more. In Iraq between 1990-1994, infant deaths had shown this reality in its more bare form with an increase of 600% (4). The war taking five years increases the child deaths under age of 5 by 13%. Also 47% of all the refugees in the world and 50% of asylum seekers and displaced people are women and girls and 44% refugees and asylum seekers are children under the age of 18 (5) . As the result of wars and armed conflicts, women are
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Capsella bursa-pastoris is an annual and ruderal flowering plant from Cruciferae's family (13) and contains minerals, vitamin A, ascorbic acid, protein, linoleic acid, polyunsaturated ⍵3 fatty acid, magnesium, iron, vitamin B and C (14) . In texts related to herbs and traditional medicine, this plant has been considered as an antibleeding and astringent medicine and its useful effects have been reported in chronic menorrhagia and uterine bleeding treatment (13) (14) (15) , anxiety treatment, and rapid recovery of wounds (16, 17) . C. bursa-pastoris can be effective on smooth muscles of uterus and increase their contraction. Having hypochlorite effect, it is used orally for the treatment of uterus and severe bleedings (18, 19) . The hemostatic effects of this plant are exerted through several mechanisms including stimulation of uterus contractions, contraction of capillaries, stimulation of prothrombin production, and reduction of fragility in capillaries (20) . Moreover, C. bursa-pastoris has oxytocin synergic effects (21) , and oxytocin plays an important role in human's excitement, orgasm and increase of sexual responses (22, 23) . It seems that due to these biochemical features, oxytocin can be effective in bleeding amount and accordingly sexual functioning. Despite the effect of sexual relationships on human's physical and mental health, paying inadequate attention to sexual issues in Iran is completely conspicuous. In the same vein, failure of pregnancy prevention methods can be due to sexual disorders resulted from pregnancy prevention disorders. All these reasons provided motivation for designing a research with the aim of determining the effect of C. bursa-pastoris on sexual functioning in copper IUD users to improve the score of sexual function, avoid early removal of IUD and increase the acceptance of this tool in community.
Materials and Methods

Study Type and Participants
This study was part of a controlled random triple blind clinical trial in which sexual functioning was investigated as a secondary consequence. The studied population were the females in the age range of 15-40 years visiting healthcare centers of Ardebil city, Iran, since early March till July 2015.
The eligible criteria for doing the study included: abnormal menstrual bleeding at least for 3 months after IUD insertion, absence of systemic diseases according to the individual's remarks (thyroid disease, myoma, hyperprolactinaemia, etc), absence of uterine myoma according to the individual's remarks, absence of drug reaction to mefenamic acid, regular menstrual cycle before IUD insertion, a minimum proficiency level at reading and writing, having inclination toward participating in the study, and having informed consent letter.
Sample Size According to the available data from a previous study by Mirghafourvand et al (24) , and considering the sexual functioning score before the intervention (m1 = 65.9) and with presumption of 20% increase in sexual functioning score (m2 = 79.08, sd1 = sd2 = 8.15 and α = 0.05, power = 95%), the sample size for each group was considered 39, and with possibility of 10% decrease, the final sample size was considered 45.
Randomization and Intervention
The samples were divided into 2 groups of mefenamic acid (n = 46) and C. bursa-pastoris (n = 44) by using computerized random numbers and through quadruple and sextet blockings. The division order was done by an individual who was not involved in the study and by the use of randomizer program. For the members in C. bursa-pastoris group, 3 pills each containing 700 mg the powder of plant (the total of the plant) for duration of 3 cycles (since the first day of period till day 7 or at the end of bleeding in cases less than 7 days) were prescribed and for the mefenamic acid group, the pills containing 500 mg were prescribed with the same instruction. For preparing the C. bursa-pastoris, bursa-pastoris plant was purchased from Tabriz drug market during April 2015 and after identification, it was powdered by grinder in botany laboratory of the Faculty of Pharmacy at Tabriz University of Medical Sciences. Then, according to the considered dose of pills, the appropriate amount of bursa-pastoris plant was mixed with appropriate amount of gelatin liquid and sifted from mesh sieve 10 in a wet state and after that, about 30% of weighted microcrystalline powder was added to the prepared granules and an amount of 3% sodium starch glycolate as an opener and 1% magnesium stearate as a lubricant were added and pressed by a machine into pills containing 700 mg bursa-pastoris plant. The mefenamic acid pills were prepared according to the same method each pill containing 500 mg mefenamic acid. The required mefenamic acid powder was prepared by Alhavi Pharmaceutical Co., Tehran, Iran. Both of the pills were the same in terms of appearance (shape, color, smell).
Sampling
Sampling was done after that Ethics Code was obtained from the Ethics Committee of Tabriz University of Medical Sciences. Ardebil has 21 healthcare centers in total and sampling was done from 14 centers located in various areas of Ardebil with different social and economic statuses. At the first stage, a checklist was prepared according to IUD offices by females at the age range of 15-45 who had IUD and 3 months had passed form their IUD insertion. Then, these people were contacted, and was asked from the ones who were dissatisfied with bleeding due to copper IUD to visit the corresponding healthcare center in the case of having inclination toward participating in the study. For considering research-ethics issues, at the beginning of the study, the objectives, design and methodology were explained to the qualified women and the conditions of inclusion in the study was described to the participants. After obtaining the written informed consent letter, social-individual characteristics questionnaire and Higham chart along with required explanations for filling it out and the same sanitary napkin were made available to people by the researcher and they were requested to bring back the completed questionnaires after one month. According to the Higham chart, individuals who obtained scores higher than 100 were entered into the study and the sexual functioning questionnaire was filled for them. For each participant, there was 3 small packets containing drugs that each of them was prepared for one month and the small 3 packets were inside a big pale and tandem packet which was numbered in order. After the end of third period bleeding, and after the intervention initiation, the packets of drugs were received and the sexual functioning questionnaires were filled out again. It is noteworthy that according to the reports of studies, for achieving an acceptable result from the drugs, at least 3 months is demanded and at most it is achieved during 6 months or more. Accordingly, in this study, prescription of drugs was continued for 3 cycles. For assuring drug's use and completing the questionnaires, the participants were examined every 2 weeks through phone contacts. The questionnaire was filled out by the participant herself.
Data Collection Tool
In this study for data collection, social-individual questionnaire, and sexual functioning (FSFI) and secondary side effects questionnaire were used. Higham graphic chart's questionnaire or Pictorial Blood Lost Assessment Chart (PBAC) were used for bleeding assessment. Higham chart is a chart in which the first horizontal row shows the number of period days and the vertical row shows the pads soaked in blood with 3 degrees of mild, moderate, and severe. For the mild degree, coefficient 1; for moderate degree, coefficient 5; and for severe degree, coefficient 20 (pads completely soaked in blood) were considered. In addition, small clots (size of a 1p coin) and large clots (size of a 50p coin) are scored as 1 point and 5 points, respectively and for the removal of blood flow (to contaminate underwear or blood flow in restroom), score 5 were considered. At the end of period, each sign was multiplied by the corresponding coefficient and the calculated numbers were collected and the total score was obtained. The score of 100 and above, referred to bleeding more than 80 mm and score less than 100 showed less bleeding. This method with sensitivity of 86% and specificity of 89% was an effective method for separation of menorrhagia from normal menstrual bleeding. The reliability and validity of Higham chart were verified by Moukhah et al (25) in Iran.
Sexual functioning was measured through a 19-case comprehensive questionnaire developed by Rosen et al (26) (Female Sexual Functioning Index). The reliability and validity of its Persian version was verified by Mohammadi et al (27) . This standard questionnaire measures the sexual functioning in 6 domains of desire, arousal, humidifying, orgasm, sexual satisfaction and pain during the recent 4 weeks. These sub-branches, have response spectra of 0, 5, and 1. Score 0 indicates the absence of sexual relationship during the last 4 weeks and score 5 indicates the maximum satisfaction from sexual relationship in each domain. According to the instructions of questionnaire designer, the scores of each domain can be achieved through adding up the scores of questions in each domain, then their multiplication by the factor number. By adding up the scores of these 6 domains, the total score scale is obtained. Balancing the scores, the maximum score for each domain equals to 6 and for the total scale, it would be 36. Zero is demonstrative of the issue that the person did not have sexual activity during the last 4 weeks and high score demonstrates more desirable sexual functioning.
Data Analysis
The data were analyzed using SPSS version 21.0. Normality of the quantitative variables were examined using Kolmogorov-Smirnov test which was normal. For comparison of individual-social characteristics among the groups, independent t test, Chi-square, Fisher exact test, and round chi-square were used. For comparing the sexual functioning score, before intervention, independent t test and after intervention, analysis of covariance (ANCOVA) test were used with controlling the base values. A P value > 0.05 was considered significant.
Results
Sampling and pursuing the research samples was initiated since early April 2015 and continued till late November 2015. In total, among 1036 women who were qualified according to IUD offices of healthcare centers, 385 women due to lack of visiting centers, 268 women due to unwillingness to take part in the study (the major reason was mentioned their husband's dissatisfaction) and 293 women due to lack of criteria for entering into the study including absence of reading and writing skills, presence of uterine myoma, obtaining scores less than Higham chart, etc were excluded from the study. The remained 90 women were divided into 2 groups of mefenamic acid and bursa-pastoris. In total, 46 females in mefenamic acid group and 44 females in bursa-pastoris group successfully completed 3 months of pursuing (Figure 1) .
In this study, 90 women were analyzed and sample loss did not occur in the groups. There was not any significant statistical difference between 2 groups considering 195 individual-social characteristics (P > 0.05). The average age of participants was 31.2 (5.4), most of the participants (82.2%) were house wives, and 40% had high school diploma ( Table 1) .
The mean of sexual functioning score was 23.39 (4.18) in Mefenamic acid group before intervention, which was increased to 24.24 (3.45) in the third cycle of treatment. In bursa-pastoris group, the mean of sexual functioning was 21.40 (4.70) which was increased to 24.85 (3.81) in the third cycle of treatment (after finishing the intervention). The adjusted difference was 0.60 (95% CI, -0.19-2.13 ) after intervention (Table 2) .
Discussion
In spite of fairly high prevalence of sexual functioning problems in females, there have been a few laboratory trials using medicinal interventions for its prevention and treatment (28) (29) (30) .
The findings of the current study demonstrated that mefenamic acid and bursa-pastoris were both capable of increasing sexual functioning score at the end of third cycle after intervention and this increment was significant in bursa-pastoris group. Due to the lack of studies for investigation of C. bursa-pastoris effect on sexual functioning so far, similar studies were used in the present study (drugs or plants with similar effectual mechanism or similar effective material and disease with similar pathology).
In a study by Amiri et al which was carried out in Tehran, Ginkgo biloba oral capsule led to the improvement of sexual functioning in menopausal females and there was a significant difference among the mean scores of desire to sexual relationship, sexual activity, sexual satisfaction, arousal and orgasm in last month, before and after the use of G. biloba capsule (31). Ito et al in a laboratory triple-blind trial showed that making use of Max arginine supplement which contains G. biloba extraction, multivitamin and minerals, improved sexual satisfaction, sexual desire, vaginal dryness, the number of sexual activity, orgasm and sensitivity of clitoris after 4 weekss (32) . In a study which was done by Naafe et al, at Shahid Beheshti University of Medical Sciences in Tehran, it was reported that hydroalcoholic extraction of shoots of bursa-pastoris was effective in reducing menstrual bleeding and treating idiopathic menorrhagia (33) . In a study by Sourteji et al, the hydroalcoholic extraction of nettle and mefenamic acid reduced the amount of uterine bleeding and this reduction was significant in nettle group (34) .
The bursa-pastoris extraction contains various materials including Tannins, choline, acetylcholine sterols and flavonoids (35) . This plant also has oxytocin synergic effects (21) . Moreover, IUD reduces the number of intercourse and sexual functioning through increasing irregular uterine bleeding. Therefore, this plant through reducing irregular period bleeding also leads to sexual functioning improvement. Bursa-pastoris like G. biloba contains flavonoids (18) and it seems that it plays an effective role, through similar mechanism, in the improvement of sexual functioning. Furthermore, due to having mineral materials, iron, magnesium, vitamins A, B and C, it can result in increment of sexual functioning like Max arginine supplement. Bursa-pastoris also has inflammatory properties like nettle (1) and it seems effective in bleeding treatment and accordingly in sexual functioning improvement through similar mechanism. The major role of plants in treating some females' illnesses is through their impact on body hormones. The investigations have shown that important combinations of plants including flavonoids directly affect pituitary gland, and cause the increase of pituitary hormones' level (oxytocin) and they can balance disorders which may occur due to the loss of hormones. In addition, oxytocin plays a significant role in human's arousal, increment of orgasm and sexual responses (22, 23) . According to the findings of this study, C. bursa-pastoris can be effective in abnormal period bleeding reduction and sexual functioning increment at the same level as mefenamic acid which can be a good alternative due to side effects of chemical and non-steroidal anti-inflammatory drugs. This intervention was used for a duration of 3 months on females, but regarding the long-term impact of herbal drugs, it is recommended to carry out the study on sexual functioning for longer periods of time.
Conclusions
The findings of this study demonstrated that bursapastoris led to the increment of sexual functioning score in copper IUD users. Considering that bursa-pastoris did not have any side effect, and women mostly prefer to take complementary medicines, this plant can be safely used in sexual functioning improvement. All data are represented in %, except for those identified by *. 
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